IRIS
LO COCO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 125.760
EU - Europa 7.605
AS - Asia 4.208
SA - Sud America 55
Continente sconosciuto - Info sul continente non disponibili 46
OC - Oceania 17
AF - Africa 14
Totale 137.705
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 125.721
SG - Singapore 2.047
UA - Ucraina 1.555
CN - Cina 1.283
DE - Germania 1.192
IE - Irlanda 1.079
PL - Polonia 784
KR - Corea 691
IT - Italia 682
RU - Federazione Russa 556
FR - Francia 546
GB - Regno Unito 384
FI - Finlandia 371
SE - Svezia 291
NL - Olanda 36
EU - Europa 35
BE - Belgio 34
CA - Canada 32
JP - Giappone 30
BR - Brasile 27
IN - India 27
CL - Cile 19
ID - Indonesia 17
AT - Austria 16
VN - Vietnam 16
AU - Australia 15
HK - Hong Kong 13
SK - Slovacchia (Repubblica Slovacca) 13
IR - Iran 12
A2 - ???statistics.table.value.countryCode.A2??? 9
PH - Filippine 9
CH - Svizzera 8
ES - Italia 8
RO - Romania 8
TR - Turchia 8
CZ - Repubblica Ceca 7
KG - Kirghizistan 7
MX - Messico 7
UZ - Uzbekistan 7
MA - Marocco 6
GR - Grecia 5
NO - Norvegia 5
AE - Emirati Arabi Uniti 4
EG - Egitto 4
HU - Ungheria 4
LT - Lituania 4
MY - Malesia 4
PT - Portogallo 4
RS - Serbia 4
AR - Argentina 3
BD - Bangladesh 3
DK - Danimarca 3
LK - Sri Lanka 3
PE - Perù 3
PK - Pakistan 3
SA - Arabia Saudita 3
TW - Taiwan 3
A1 - Anonimo 2
AM - Armenia 2
BY - Bielorussia 2
EC - Ecuador 2
ET - Etiopia 2
IL - Israele 2
IQ - Iraq 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NZ - Nuova Zelanda 2
QA - Qatar 2
AL - Albania 1
AZ - Azerbaigian 1
EE - Estonia 1
JO - Giordania 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
SC - Seychelles 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
Totale 137.705
Salva come PNG Salva come JPEG
Città #
Woodbridge 40.476
Wilmington 33.239
Houston 30.671
Fairfield 3.701
Ann Arbor 3.125
Chandler 2.032
Singapore 1.743
Ashburn 1.599
Seattle 1.548
Cambridge 1.310
Jacksonville 1.164
Dublin 1.048
Dearborn 1.007
Medford 821
Kraków 771
Beijing 535
Santa Clara 387
Lawrence 385
New York 309
Rome 214
San Diego 177
Moscow 146
Zhengzhou 107
Hangzhou 102
Milan 102
Mülheim 95
Norwalk 86
Menlo Park 81
Hefei 70
London 65
Mountain View 62
Redwood City 62
Boardman 60
Verona 60
Shanghai 44
Nanjing 42
Kunming 37
Guangzhou 35
Brussels 31
Creede 31
Falls Church 25
Fuzhou 25
Chicago 23
Los Angeles 23
San Francisco 23
Nuremberg 22
San Mateo 22
Helsinki 21
Jinan 21
Nanchang 20
Toronto 20
University Park 20
Indiana 19
Chengdu 17
Hounslow 17
Saint Petersburg 17
Jakarta 16
Center 15
Bologna 14
Groningen 14
Phoenix 14
Kilburn 13
São Paulo 13
Wuhan 12
Chiswick 11
Palo Alto 11
Dong Ket 10
Washington 10
Detroit 9
Redmond 9
Changsha 8
Amsterdam 7
Auburn Hills 7
Hebei 7
Innsbruck 7
Munich 7
Prescot 7
Seoul 7
Tokyo 7
Council Bluffs 6
Hong Kong 6
Kosice 6
Nürnberg 6
Quzhou 6
Shenyang 6
Shenzhen 6
Ypsilanti 6
Brescia 5
Brno 5
Cedarhurst 5
Hanoi 5
Hanover 5
La Canada Flintridge 5
Leawood 5
Lodi 5
Manila 5
Montreal 5
Mumbai 5
Nanning 5
Taiyuan 5
Totale 128.263
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 555
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer 458
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 453
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation 451
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 451
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 448
A systems medicine clinical platform for understanding and managing non- communicable diseases 448
A case of SRSF2 mutation in chronic lymphocytic leukemia 447
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia 446
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells 443
MiR-21 is overexpressed in NPM1-mutant acute myeloid leukemias 442
Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: Impact on response to chemotherapy 441
What is the standard regimen for patients with acute promyelocytic leukemia? 441
"Composite" lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin 441
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies 438
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. 437
A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes 436
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 435
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide 435
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 433
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen 432
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients with Arsenic Trioxide and Retinoic Acid in the United States 431
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 430
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 429
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 427
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 426
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy 426
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 426
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. 425
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 424
Current management of newly diagnosed acute promyelocytic leukemia 423
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors 423
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 423
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 421
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts 420
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 418
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL 418
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet 417
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23) 417
Idiopathic hypereosinophilic syndrome: A case evolving in B-lymphoblastic lymphoma 417
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 416
BCL-6 and the molecular pathogenesis of B-cell lymphoma 416
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission 416
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression 415
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 415
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 415
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy 412
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 412
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. 412
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid 412
Acute myeloid leukemia developing in patients with autoimmune diseases. 411
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 411
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 411
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia 411
Molecular characterization of Ph' + hybrid acute leukemia 411
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 411
Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms 411
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome [10] 410
Podocalyxin is expressed in normal and leukemic monocytes 410
Panobinostat for the treatment of acute myelogenous leukemia 408
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels 407
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia 407
Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men 407
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes 406
Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia 406
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy 406
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene 406
GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children 405
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia 405
High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia 405
The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations 405
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? 405
Absence of HHV-8 DNA sequences in malignant mesothelioma 405
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 405
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. 404
History of acute promyelocytic leukemia: a tale of endless revolution 403
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo 403
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia 403
Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease 402
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias 401
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms 400
Frequency of RAS and p53 mutations in acute promyelocytic leukemias 400
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype 399
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis 398
Thrombo-hemorrhagic deaths in acute promyelocytic leukemia 398
Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia 398
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma 398
Arsenic trioxide: its use in the treatment of acute promyelocytic leukemia 397
High-mobility group A1 proteins are overexpressed in human leukaemias 397
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients 397
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective 396
RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia 396
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease 396
Clonal evolution in therapy-related neoplasms 396
Current treatment of acute promyelocytic leukemia. 395
Molecular genetics of the t(15;17) translocation in acute promyelocytic leukemia 395
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. 394
Molecular monitoring of hematologic malignancies: current and future issues 394
Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status 394
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients 393
Totale 41.725
Salva come PNG Salva come JPEG
Categoria #
all - tutte 255.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 255.623
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202021.390 0 0 0 0 0 4.078 3.442 3.283 3.213 2.868 1.960 2.546
2020/202119.108 2.077 2.389 2.084 2.576 1.999 2.025 2.262 1.825 500 360 829 182
2021/20223.670 152 522 124 163 94 232 222 185 210 286 404 1.076
2022/20235.059 580 256 188 622 452 1.222 445 357 545 39 246 107
2023/20241.512 230 76 118 35 181 368 33 112 17 32 14 296
2024/20253.758 286 1.980 889 382 80 141 0 0 0 0 0 0
Totale 138.839